

DR. LYNDA MYRA OLUOCH, MBChB, MPH, MSc
CLINICAL RESEARCH SCIENTIST | CLINICAL RESEARCH COORDINATOR |
CLINICAL TRIAL OPERATIONS

Nairobi, Kenya | +254 720 815 942 | oluochlynda8@gmail.com | ORCID: 0000-0002-3105-8892

PROFESSIONAL PROFILE

Medical doctor and clinical research scientist with 10+ years of experience in clinical research and global health, including extensive experience in vaccine research, HIV/STI prevention, HPV and cervical cancer, adolescent and reproductive health, and implementation research. Experienced in coordinating and implementing multicentre clinical studies from protocol implementation and site initiation through participant engagement, safety oversight, regulatory and ethics submissions, quality management, data review, documentation, dissemination and close-out.

Strong working knowledge of ICH-GCP, human-subject protection, epidemiology, study design and implementation science, with experience coordinating investigators, sponsors, clinical teams, laboratories, regulators and community-facing stakeholders. Contributor to 17+ peer-reviewed publications and 20+ national and international scientific meetings.

Solid combination of clinical expertise, clinical trial coordination, implementation science, regulatory oversight, stakeholder engagement and scientific communication, with a strong interest in strengthening research systems and translating evidence into sustainable health interventions.

CORE EXPERTISE

Clinical trials • Clinical research project management • Protocol implementation • Study start-up/site activation • Clinical operations • ICH-GCP & human-subject protection • IRB/ethics & regulatory submissions • Safety procedures & reporting • Participant engagement • Investigator & multidisciplinary team coordination • Site performance & quality management • SOPs and study documentation • Epidemiology & study design • Implementation research • Stakeholder & partner management • Scientific writing & publications • Conference presentations • Evidence translation • Proposal/funding support

PROFESSIONAL EXPERIENCE

CLINICAL RESEARCH COORDINATOR / CLINICAL STUDY MANAGER | *Kenya Medical Research Institute (KEMRI-PHRD), Nairobi* | July 2016 – June 2026

- Served as a review committee **member of the Scientific and Ethics Review Unit (SERU), the KEMRI IRB**. Participated in review and discussion of research protocols, with consideration of scientific validity, ethical principles, informed consent, participant safety and regulatory requirements.
- Coordinated clinical study implementation across sites, including protocol execution, study documentation, participant engagement, clinical team coordination, timelines, enrolment targets, operational risks and issue escalation.
- **Clinical research oversight:** Supported research programmes from site preparation and initiation through implementation, monitoring, dissemination, and close-out, ensuring alignment between protocols, SOPs, regulatory requirements and day-to-day site operations.
- **Site initiation and readiness:** Led and supported **site initiation training and readiness activities**, preparing multidisciplinary teams to understand study objectives, protocols, participant pathways, study tools, documentation requirements, safety procedures and operational responsibilities.

- **Research team capacity development:** Trained and mentored **healthcare workers, research staff, study coordinators and multidisciplinary clinical teams** on protocols, SOPs, GCP, human-subject protection, study procedures and quality requirements.
- **SOP and implementation capacity:** Developed, reviewed and implemented **SOPs, study tools, training materials and operational guidance**, including refresher training and targeted support to address implementation gaps, protocol deviations and quality issues.
- **Regulatory and ethics oversight:** Coordinated ethics and regulatory submissions, amendments, approvals and follow-up, working with investigators, research teams, regulatory bodies and institutional stakeholders to maintain study compliance.
- **Operational leadership and quality improvement:** Coordinated investigator and study-team meetings, operational reviews and stakeholder updates, using these forums to identify bottlenecks, troubleshoot implementation challenges, monitor milestones and support continuous quality improvement.
- **Stakeholder and systems engagement:** Worked across community, facility, county and national levels (NCCP, NCI), engaging healthcare providers, county health leadership, policymakers, technical partners and other stakeholders to strengthen study implementation, ownership and sustainability. Support dissemination activities designed to communicate research findings and facilitate evidence uptake.
- **Research dissemination and evidence translation:** Supported dissemination of research findings through scientific, county and stakeholder forums, helping translate research evidence into practical understanding of interventions, implementation barriers and potential scale-up. Contributed to 17+ peer-reviewed publications and presented research at 20+ national and international scientific meetings, including invited/plenary presentations.

SELECTED CLINICAL RESEARCH PROJECTS COORDINATED

MERCK IV Study (<https://clinicaltrials.gov/study/NCT05435209>) | *KEMRI / MSD | Observational longitudinal cohort*

- Observational study assessing the effects of HPV vaccination in young people living with HIV in Kenya.
- Assessed effectiveness and B-memory cell response to quadrivalent HPV vaccine approximately nine years post-vaccination among HIV-infected boys and girls vaccinated at ages 9–14 years.
- Contributed to clinical research implementation, participant follow-up, study documentation and evidence generation around HPV vaccine responses in a population with HIV.

KEN SHE – Single-Dose HPV Vaccine Trial (<https://clinicaltrials.gov/study/NCT03675256>) | *Multicentre randomized clinical trial | Kenya*

- Multicenter randomized clinical trial evaluating a single-dose HPV vaccination strategy among young women in Kenya.
- Coordinated field implementation, clinical teams, participant engagement and study documentation, with responsibility for protocol implementation, safety procedures and stakeholder communication.
- Contributed to evidence generation that informed understanding of single-dose HPV vaccination, including practical considerations for implementation and scale-up.
- Supported dissemination of findings contributing to the evidence base for HPV vaccination policy and implementation.

Phase 3b SIIPL Quadrivalent HPV Vaccine Trial (<https://clinicaltrials.gov/study/NCT06281119>) | *Clinical research study in women living with HIV | Kenya*

- Sub-Investigator on a Phase 3b, partially double-blind, randomized, multicountry study assessing immunogenicity, safety and reactogenicity of SIIPL quadrivalent HPV vaccine in women living with HIV aged 15–25 years.
- Study compared immune responses (GMT) to HPV types 16 and 18 between participants receiving three doses of SIIPL qHPV and three doses of Gardasil®.
- Contributed to clinical oversight, participant safety, protocol implementation, study documentation and delivery of research activities in accordance with GCP and applicable requirements.

HPV Vaccination Implementation Research | *Mixed-methods implementation research* | Kenya

- Explored healthcare-provider knowledge, perceptions, acceptability, barriers and facilitators related to HPV vaccination implementation.
- Contributed to qualitative research design, data collection, analysis and synthesis, translating findings into actionable recommendations for vaccination implementation.
- Provided insight into provider perspectives and practical implementation barriers relevant to introducing and scaling vaccination interventions.

TIBA Cervical Cancer Prevention Study (<https://clinicaltrials.gov/study/NCT05472311>) | *Multicentre implementation / clinical research programme* | Kenya

- Prospective stepped-wedge cluster randomized trial evaluating cervical cancer screening and treatment implementation across facilities. Supported implementation of a multicenter programme evaluating HPV-based screening and screen-and-treat approaches for cervical cancer prevention.
- Coordinated site-level operational activities across participating facilities. This included site performance, clinical and laboratory stakeholders, quality assurance, timelines, regulatory documentation and evidence-generation activities. Identified operational bottlenecks affecting screening, HPV testing, treatment and referral pathways and coordinate solutions with facility and county teams. Supported capacity strengthening around HPV screening, diagnostic pathways, treatment/referral and implementation requirements. Contributed to stakeholder dissemination and county-level engagement.

CASCADE clinical trial studies (<https://cascade-network.org/public/>) | *Multicentre implementation / clinical research programme* | Kenya

- Clinical trials to be conducted on women living with HIV with four major scientific focus areas: increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments for cervical cancer prevention in women living with HIV.
- Coordinated site initiation training in 4 health facilities. Contributed to SOP and documentation standardisation across these sites. Supported laboratory coordination involving Abbott Alinity m and Seegene Allplex II platforms. Contributed to implementation of standardised clinical and laboratory procedures.

Additional Clinical Research Portfolio | *KEMRI-PHRD* | 2016–2026

- Clinical research spanning HIV prevention and treatment, PrEP, STI acquisition/persistence, adolescent and reproductive health, HPV/cervical cancer prevention, diagnostics and implementation science.
- Experience with HPV-related laboratory and diagnostic platforms including Abbott Alinity, Seegene and Amplicon sequencing, as well as HPV antibody testing in vaccine research. Studies include:

- Towards a Therapeutic Human papillomavirus Vaccine: Delving into Immune 2 Correlates via Human Leukocyte Antigen Typing using five-year PAXgene 3 collected archived sample of Thika-based cohort-done in KAVI
- Feasibility pilot of a highly multiplexed amplicon sequencing platform for high-risk human papillomavirus genotyping in Kenya-done at Centre for Viral Research (KEMRI)
- Factors Promoting HPV Persistence in Young Women After Initiation of Sexual Activity- done at Florian Hladik's Lab (University of Washington)

BRANCH MANAGER / MEDICAL OFFICER | *Avenue Healthcare Services, Kenya* | November 2010 – June 2016

- Managed day-to-day healthcare branch operations while providing clinical care, supervising staff, coordinating resources and maintaining service and quality standards.
 - Managed branch-level service delivery, quality and operational performance.
 - Coordinated staff, patients, suppliers and other stakeholders.
 - Supported implementation of clinical and operational policies and procedures.
 - Managed operational resources and contributed to business and service-development activities.
 - Developed experience in balancing clinical quality, patient experience, operational realities and organisational objectives.
- Resolved operational issues in a fast-paced healthcare environment and coordinated communication between clinical teams, management and patients.
- Supported health education and community-facing activities and worked with multidisciplinary teams to deliver clinical services.

MEDICAL OFFICER / INTERNSHIP | *Ministry of Medical Services, Kenya* | January 2009 – October 2010

- Provided clinical care across medicine, surgery, paediatrics and obstetrics/gynecology in a public-sector hospital setting.
- Supported public health, vaccination, community outreach and health education activities and worked within multidisciplinary clinical teams.

EDUCATION

- Master of Public Health (MPH), Global Health — University of Washington, 2020–2021
- Master of Science (MSc), Tropical and Infectious Diseases — University of Nairobi, 2013–2015
- Bachelor of Medicine and Bachelor of Surgery (MBChB) — University of Nairobi, 2003–2008

SCIENTIFIC OUTPUT & DISSEMINATION

- 17+ peer-reviewed publications across HPV vaccination, cervical cancer prevention, HIV/STIs, adolescent health and implementation science.
- Selected journals include NEJM Evidence, The Lancet HIV, Journal of Adolescent Health, Implementation Science, JNCI Monographs and PLOS Global Public Health.
- Presented research at 20+ national and international scientific meetings, including CROI, Global Vaccine and Immunization Research Forum, AIDS, HIVR4P and the International Papillomavirus Conference.
- Plenary/invited speaker at scientific and research meetings including the African-Caribbean Cancer Consortium Conference, Mombasa Research Collaborative Meeting and HIV Scientific Forum.

PROFESSIONAL CREDENTIALS & TRAINING

- Registered Medical Practitioner — Kenya Medical Practitioners and Dentists Council (KMPDC)
- Good Clinical Practice; Human Subjects Protection — CITI
- Fundamentals of Global Health Research, Advanced Track — University of Washington
- Leadership and Management — University of Washington
- Global Health Delivery — Harvard University
- Implementation Science School — Global Alliance for Chronic Diseases
- Member — Kenya Medical Association; Bioethics Society of Kenya; Africa Bioethics Network; KESHO (Kenya Society of Hematology & Oncology)
- Invited Editorial Board Member, BMC Women's Health

SELECTED PUBLICATIONS (ORCID: 0000-0002-3105-8892)

1. Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, Galloway DA, Pinder LF, Donnell D, Wakhungu I, Congo O, Biwott C, Kimanthi S, **Oluoch L**, Heller KB, Leingang H, Morrison S, Rechkina E, Cherne S, Schaafsma TT, McClelland RS, Celum C, Baeten JM, Mugo N. Efficacy of single-dose HPV vaccination among young African women. *NEJM Evid.* 2022 Jun;1(5):EVIDoA2100056. doi: 10.1056/EVIDoA2100056. Epub 2022 Apr 11. PMID: 35693874; PMCID: PMC9172784.
2. Casmir E, Daniel AK, Ongolly F, Thuo N, **Oluoch L**, Kiptinness C, Wald A, Mugo NR, Roxby AC, Ngure K. Protection at First Sexual Intercourse Among Adolescent Girls and Young Women in Kenya. *Arch Sex Behav.* 2021 Jan;50(1):219-227. doi: 10.1007/s10508-020-01785-w. Epub 2020 Jul 27. Erratum in: *Arch Sex Behav.* 2020 Sep 4;: PMID: 32720186; PMCID: PMC8024200.
3. Heffron R, Ngure K, Velloza J, Kiptinness C, Quame-Amalga J, **Oluoch L**, Thuo N, Njoroge J, Momanyi R, Gakuo S, Mbugua S, Morrison S, Haugen H, Chohan B, Celum C, Baeten JM, Mugo N. Implementation of a comprehensive safer conception intervention for HIV-serodiscordant couples in Kenya: uptake, use and effectiveness. *J Int AIDS Soc.* 2019 Apr;22(4):e25261. doi: 10.1002/jia2.25261. PMID: 30957420; PMCID: PMC6452026.
4. **Oluoch LM**, Roxby A, Mugo N, Wald A, Ngure K, Selke S, Chohan B, Kiptinness C, Tapia K, Micheni M, Maina SG, Casmir E. Does providing laboratory confirmed STI results impact uptake of HIV pre-exposure prophylaxis (PrEP) uptake among Kenyan adolescents girls and young women? A descriptive analysis. *Sex Transm Infect.* 2021 Sep;97(6):467-468. doi: 10.1136/sextrans-2020-054637. Epub 2020 Sep 11. PMID: 32917766; PMCID: PMC8132579.
5. Yuh T, Micheni M, Selke S, **Oluoch L**, Kiptinness C, Magaret A, Chohan B, Ngure K, Wald A, Mugo NR, Roxby AC. Sexually Transmitted Infections Among Kenyan Adolescent Girls and Young Women With Limited Sexual Experience. *Front Public Health.* 2020 Jul 14;8:303. doi: 10.3389/fpubh.2020.00303. PMID: 32766197; PMCID: PMC7381162.
6. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. *Lancet HIV.* 2021 Mar;8(3):e130-e137. doi: 10.1016/S2352-3018(20)30307-6. PMID: 33662265; PMCID: PMC8289198.
7. Hughes SM, Levy CN, Calienes FL, Martinez KA, Selke S, Tapia K, Chohan BH, **Oluoch L**, Kiptinness C, Wald A, Ghosh M, Hardy L, Ngure K, Mugo NR, Hladik F, Roxby AC. Starting to have sexual intercourse is associated with increases in cervicovaginal immune mediators in young women: a prospective study and meta-analysis. *Elife.* 2022 Oct 25;11:e78565. doi: 10.7554/eLife.78565. PMID: 36281966; PMCID: PMC9596159.
8. Melody Wang; Kenneth Tapia; **Lynda M. Oluoch**; Murugi Micheni; Stacy Selke; Catherine Kiptinness; Bhavna Chohan; Anna Wald; Kenneth Ngure; Nelly R. Mugo et al. Adolescent Girls and Young Women

in Kenya Demonstrate Rapid STI Incidence Following First Sex: Data From a Longitudinal Cohort. *Journal of Adolescent Health* 2023-01 | Journal article DOI: 10.1016/j.jadohealth.2022.10.026 Part of ISSN: 1054-139X

9. **Oluoch, L.**, Tapia, K., Kiptinness, C., Casmir, E., Maina, S. G., Makena, L., ... & Roxby, A. (2023). Longitudinal assessment of bacterial vaginosis prior to and during incident pregnancy: an observational study in Kenyan adolescent girls and young women. *BMJ open*, 13(10), e071746.
10. Shin, M.B., **Oluoch, L.M.**, Barnabas, R.V. et al. Implementation and scale-up of a single-visit, screen-and-treat approach with thermal ablation for sustainable cervical cancer prevention services: a protocol for a stepped-wedge cluster randomized trial in Kenya. *Implementation Sci* 18, 26 (2023). <https://doi.org/10.1186/s13012-023-01282-3>
11. Sycuro L, Lithgow K, Cochinamogulos A, Muirhead K, Konschuh S, **Oluoch L**, Mugo N, Roxby A Glycogen-Degrading pullulanase a is variably present and correlated with lactic acid in vaginal samples from young african women. *American Journal of Obstetrics and Gynaecology* · Feb 1, 2023
12. Roxby AC, Mugo NR, **Oluoch LM**, Tapia K, Wang M, Selke S, Chohan B, Micheni M, Sycuro L, Yuh T, Casmir E, Kimani E, Maina SG, Kiptinness C, Nguni K, Wald A. Low prevalence of bacterial vaginosis in Kenyan adolescent girls, and rapid incidence after first sex. *American Journal of Obstetrics and Gynecology* (2023), doi: <https://doi.org/10.1016/j.ajog.2023.06.044>.
13. Daniel, A.K., Casmir, E., **Oluoch, L.** et al. "I was just concerned about getting pregnant": Attitudes toward pregnancy and contraceptive use among adolescent girls and young women in Thika, Kenya. *BMC Pregnancy Childbirth* 23, 493 (2023). <https://doi.org/10.1186/s12884-023-05802-3>
14. Umutesi G, **Oluoch L**, Weiner BJ, Bukusi E, Onono M, Njoroge B, Mecca L, Nguni K, Mugo NR and Barnabas RV (2023). HPV vaccination in Kenya: a study protocol to assess stakeholders' perspectives on implementation drivers of HPV vaccination and the acceptability of the reduced dose strategy among providers. *Front. Health Serv.* 3:1233923. doi: 10.3389/frhs.2023.1233923
15. Hybiske K, Paktinat S, Newman K, Patton D, Khosropour C, Roxby AC, Mugo NR, **Oluoch L**, Nguni K, Suchland R, Hladik F, Vojtech L. 2024. Antibodies from chlamydia-infected individuals facilitate phagocytosis via Fc receptors. *Infect Immun* 92:e00503-23. <https://doi.org/10.1128/iai.00503-23>
16. Umutesi, G., Weiner, B. J., **Oluoch, L.**, Bukusi, E., Onono, M., Njoroge, B., ... & Barnabas, R. V. (2024). Acceptability of single-dose HPV vaccination schedule among health-care professionals in Kenya: a mixed-methods study. *JNCI Monographs*, 2024(67), 358-370.
17. Umutesi, G., Hathaway, C. L., Heitner, J., Jackson, R., Miano, C. W., Mugambi, W., ... & Barnabas, R. V. (2024). The Potential Impact of a Single-Dose HPV Vaccination Schedule on Cervical Cancer Outcomes in Kenya: A Mathematical Modelling and Health Economic Analysis. *Vaccines*, 12(11), 1248.
18. Adhiambo HF, Owidi E, Okello P, Coe M, Shin MB, **Oluoch LM**, Thuo NB, Ihaji V, Kerubo MB, Kinyua A, Caucutt J, Heitner J, Odeny T, Weiner B, Nguni K, Mugo N, Gimbel S. Barriers and facilitators to implementing a single-visit, screen-and-treat approach with thermal ablation for cervical cancer prevention in Kenya. *PLOS Glob Public Health*. 2025 Sep 9;5(9):e0005166. doi: 10.1371/journal.pgph.0005166. PMID: 40924765.

REFERENCES

Prof Marianne Mureithi

Director KAVI–Institute of Clinical Research, University of Nairobi

mmureithi@kaviuon.org

Dr Betty Njoroge

Principal Research Scientist

KEMRI-CCR Nairobi

bnjoroge@kemri.go.ke

Dr. Maricianah Onono

Principal Investigator

KEMRI-CMR Nairobi

maricianah@gmail.com

